Latest news with #GIP
Yahoo
5 days ago
- Business
- Yahoo
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Viking Therapeutics VKTX reported second-quarter 2025 loss of 58 cents per share, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 20 cents per share in the year-ago quarter. Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it it yet to generate revenues. More on VKTX's Q2 Earnings Research and development (R&D) expenses amounted to $60.2 million, compared with $23.8 million incurred in the year-ago period. This significant increase was primarily due to higher costs associated with clinical studies and manufacturing for the company's drug candidates, as well as increased employee-related expenses. General and administrative expenses amounted to $14.4 million, up 40% year over year, primarily due to higher employee-related expenses. Shares of VKTX were down 8% in after-market trading yesterday, likely due to a wider-than-expected loss incurred in the quarter on higher operating expenses. The stock has outperformed the industry so far this year, as seen in the chart below. Image Source: Zacks Investment Research As of June 30, 2025, Viking Therapeutics had cash, cash equivalents and short-term investments worth $808 million compared with $852 million as of March 31, 2025. 2025 Guidance While Viking did not provide hard numbers, it indicated on the conference call that R&D expenses are expected to rise sequentially by approximately 25% to one-third in the third and fourth quarters of 2025 compared with the second quarter. VKTX's Pipeline Updates Viking Therapeutics is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subcutaneous (SC) versions for treating obesity. Last month, Viking Therapeutics started the phase III VANQUISH program to evaluate VK2735 SC in adult patients with or without type II diabetes (T2D) for 78 weeks. The program consists of two late-stage studies — the VANQUISH-1 study will enroll obese adults with at least one weight-related co-morbid condition, while the VANQUISH-2 study will enroll obese or overweight adults with T2D. VKTX is targeting enrollment of about 4,500 participants for the VANQUISH-1 study and around 1,100 for the VANQUISH-2 study. Viking is also evaluating the oral formulation of VK2735 in the ongoing phase II VENTURE-Oral Dosing study, which spans over 13 weeks. Data from this study is expected before this year's end. Additionally, the company reiterated plans to file an investigational new drug application with the FDA in the fourth quarter of 2025 to advance an internally developed amylin agonist program to clinical development for treating obesity. VKTX's Zacks Rank Viking currently carries a Zacks Rank #3 (Hold). Viking Therapeutics, Inc. Price Viking Therapeutics, Inc. price | Viking Therapeutics, Inc. Quote Our Key Picks Among Biotech Stocks Some better-ranked stocks from the sector are Akero Therapeutics AKRO, Amarin Corporation AMRN and Agenus AGEN. While AMRN and AKRO sport a Zacks Rank #1 (Strong Buy) each at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 90 days, loss per share estimates for Akero's 2025 have improved from $4.08 to $3.93. Loss per share estimates for 2026 have narrowed from $4.30 to $4.27 during the same period. AKRO stock has surged 86% year to date. Akero's earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 48.90%. In the past 90 days, loss per share estimates for Amarin's 2025 have improved from $4.60 to $2.30. Loss per share estimates for 2026 have narrowed from $3.87 to $1.50 during the same period. AMRN stock has surged 61% year to date. Amarin's earnings beat estimates in two of the trailing four quarters, met the mark once and missed the mark on another occasion, delivering an average surprise of 29.11%. In the past 90 days, Agenus' bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 122% so far this year. Agenus' earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Time Business News
22-07-2025
- Health
- Time Business News
The Role of Sleep Quality in Mounjaro Weight Loss Outcomes: A UK Perspective
In recent years, the conversation around weight management in the UK has broadened beyond diet and exercise. Increasingly, factors such as emotional wellbeing, hormonal health, and sleep quality are being recognised as significant contributors to sustainable weight outcomes. This shift has coincided with the emergence of newer medications developed primarily for managing Type 2 Diabetes—one of the most prominent being Mounjaro (tirzepatide). While primarily indicated for blood glucose control, many individuals prescribed Mounjaro have observed notable weight loss benefits as a secondary outcome. However, to fully optimise these effects, supporting lifestyle factors like sleep quality should not be overlooked. This article explores how sleep interacts with the body's metabolic processes and how it may influence Mounjaro weight loss outcomes, particularly for those managing their health in the UK context. Mounjaro, the brand name for tirzepatide, is a once-weekly injectable medication prescribed for the management of Type 2 Diabetes. What sets Mounjaro apart from other medications is its dual action on two key gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones play a crucial role in regulating insulin secretion, appetite, and digestion. This dual receptor activity means the tirzepatide mechanism of action not only helps with glycaemic control but also reduces hunger and delays gastric emptying. These effects can contribute to modest weight loss, which has drawn attention from researchers and patients alike. Mounjaro is typically administered via the Mounjaro injection, and it is available in pen devices such as the MounjaroKwikPen, offering ease of use for patients prescribed the medication. Sleep is often seen as downtime, but metabolically, it is an active and essential process. Poor sleep quality or insufficient sleep disrupts hormonal balances that regulate hunger, insulin sensitivity, and stress. Specifically, sleep deprivation reduces leptin, the hormone responsible for satiety, while increasing ghrelin, which stimulates appetite. Moreover, lack of rest impairs insulin sensitivity, potentially leading to elevated blood glucose levels and increased fat storage. For individuals managing Type 2 Diabetes or trying to support their metabolism, sleep becomes an integral part of the equation. Given Mounjaro's role in blood sugar control and appetite regulation, there is growing interest in whether optimising sleep can enhance the medication's effectiveness, particularly in achieving sustained metabolic improvements. While clinical data directly linkingsleep quality and tirzepatide efficacy is still emerging, there is a strong biological rationale for synergy. The GLP-1 and GIP receptors targeted by Mounjaro are influenced by circadian rhythms—our body's internal clock. Poor sleep can disrupt these rhythms, potentially blunting hormonal responses. On the other hand, consistent and restorative sleep may allow these metabolic pathways to function optimally, thereby complementing the pharmacological effects of Mounjaro weight loss treatment. Moreover, fatigue from poor sleep may decrease physical activity levels or increase cravings for high-calorie foods, indirectly reducing the benefits seen from Mounjaro. Like all prescription medications, Mounjaro side effects vary from person to person. Some users report symptoms such as nausea, constipation, or fatigue, especially in the early stages of treatment. These effects, if persistent, could affect sleep quality. For example, gastrointestinal discomfort during the night may disrupt sleep cycles, and feelings of fatigue may mask deeper issues related to circadian misalignment. Patients are encouraged to report any persistent side effects to their healthcare provider, particularly if these are interfering with rest or daily functioning. In the UK, Mounjaro is approved for the treatment of Type 2 Diabetes, not explicitly for weight loss alone. It is available only by prescription and must be issued under the guidance of a qualified healthcare professional. Given the current MHRA regulations, medications like Mounjaro cannot be marketed directly for weight loss in the UK, even though weight reduction may be observed as a secondary effect. Patients interested in exploring whether Mounjaro for Type 2 Diabetes may be appropriate for their health situation should consult their GP or a specialist. Discussions should always be individualised, considering the full scope of metabolic health, including factors such as sleep. For those using Mounjaro as part of a diabetes management plan, here are a few practical strategies to enhance sleep: 1. Maintain a Regular Sleep Schedule Going to bed and waking up at the same time each day supports your circadian rhythm, which may also help stabilise hormone activity related to appetite and metabolism. 2. Limit Stimulants in the Evening Avoid caffeine, nicotine, or heavy meals close to bedtime. These can interfere with the quality of sleep and digestion—particularly important for individuals on medications affecting gastric emptying. 3. Mind the Timing of Mounjaro Injections Some patients find that the timing of the Mounjaro injection may influence when side effects like nausea or fatigue appear. Administering it at a time that allows side effects to resolve before sleep can be helpful. 4. Create a Sleep-Friendly Environment Cool temperatures, reduced light exposure, and a screen-free wind-down routine can all contribute to better sleep outcomes. 5. Stay Physically Active Regular, moderate exercise has been shown to improve sleep quality and enhance insulin sensitivity. It may also support the body's response to tirzepatide. When it comes to managing Type 2 Diabetes and supporting healthy weight outcomes, medications like Mounjaro offer a powerful tool. But pharmacological treatments rarely work in isolation. Lifestyle choices—especially adequate, high-quality sleep—can significantly influence the overall effectiveness of a treatment plan. By prioritising sleep hygiene alongside medication, physical activity, and nutrition, individuals may see more stable improvements in glucose regulation, appetite control, and body weight. As our understanding of the interplay between sleep and metabolic function continues to evolve, patients and healthcare providers alike should view rest not as a luxury, but as an essential part of therapeutic success. For patients who have been prescribed Mounjaro by a healthcare professional, Pharmacy Planet is a trusted UK-based online pharmacy offering regulated access to licensed treatments. You can buy Mounjaro, including the MounjaroKwikPen, through their platform following appropriate clinical assessment. They also provide additional information for those interested in buying tirzepatide compound under prescription. TIME BUSINESS NEWS
Indian Express
20-07-2025
- Health
- Indian Express
Gujarat to create genome database of tribal communities: what's the project, why
In a first in the country, the Gujarat government has announced a genome sequencing project to create a database from 29 tribal groups across 17 districts of the state. The exercise, a local extension of the recently completed Genome India Project (GIP), will be carried out over the next five years. The entire eastern belt of Gujarat, which shares borders with Rajasthan in the north, Madhya Pradesh in the east and Maharashtra in the south, has districts with a predominantly tribal population. The Genome India Project — its report was released by Prime Minister Narendra Modi in January — saw 10,000 genomes from 83 diverse groups processed and stored at the Indian Biological Data Centre. It had around 1,800 samples from Gujarat, which included around 100 samples from tribal communities, not enough to represent them. Thus, the Gujarat Tribal Genome Sequencing Project aims to gain critical insight into the genetic makeup of these tribal groups, which, at 15% of the state's population, consist of approximately 1 crore people. This initiative is also expected to enrich the Central Genome India dataset. The project, approved in the Gujarat budget of 2025-26, will be helmed by the Gujarat Biotechnology Research Centre (GBRC). Implications of the project Mona Khandhar, Principal Secretary, Department of Science and Technology, said the understanding of genome characteristics will help the government in making more focused programmes. Subject enrollment will take place after a formal launch of the project by Chief Minister Bhupendra Patel, so that awareness begins before field researchers go to the villages. 'Our field teams will seek help from the local administration, communities, as well as the political leadership. This is why it was important to explain the project to MPs and MLAs. We are also taking help from researchers at Birsa Munda Bhavan and the Tribal Development Department,' said a scientist involved in the project. The project's six-point agenda includes capturing the unique diversity of India's population, improving diagnosis of rare diseases, supporting development of novel drugs, developing precision medical treatments tailored to genetic profiles, building a genomic reference panel for the tribal population, and boosting public health research infrastructure. Many among the tribal communities from Gujarat have excelled in sports. Director of GBRC Prof Chaitanya Joshi said, 'These tribes can be very good in, say, archery, or skills other communities may not have. So what are the genes associated with that? With this project, skill sets associated with genes can be identified.' Health aspect Health problems like malnutrition, anaemia, low BMI, prevalence of genetic diseases like sickle cell anaemia, G6PD deficiency are common in the tribal communities in Gujarat. Scientist and Joint Director at the GBRC Amrutlal K Patel said, 'So far, the medicines developed have been studied on the western population and we haven't explored the Indian genome. Diseases are more prevalent in specific communities and ethnicity also due to the Indian tradition of endogamy, as a result of which genome variations are conserved within castes.' Patel gave an example of how deaths due to organ failure were reported in certain tribes when they crossed 30 years of age. Two years ago, the GBRC researched some patients and their first degree family members, and found this was due to the mutation of the transthyretin (TTR) gene, resulting in the aggregation of protein that reached the organs, causing failure. Some mutations increase the chances of a disease, for instance BRCA1 and 2 genes in breast cancer. These are generally detected after 50 years of age and after tests. 'We can identify these in advance and design a policy that can prevent the prevalence of breast cancer. All these measures decline the disease burden on the community and thus the state government,' a scientist said. The process As part of this project, scientists will collect samples from 4,158 individuals from various tribal communities, including data on their physical measurements and blood biochemistry, and create a 2,000-strong diverse database of tribal genomes. 'We will genotype the samples and remove those that are genetically close to each other. Out of 4,158, we will do SNP (Single Nucleotide Polymorphisms) type genotyping and take those with the most diverse genetics. The precaution is also because there might be bias during sample collection, which can then be eliminated at the analysis stage,' an official said. Of these, 378 will be trio samples. This means that samples will be taken of three members of the same family, including an individual as well as his/her biological parents. The other 3,780 will be individual samples. Apart from blood samples, stool samples will also be collected for microbial information. The role of the tribal department, according to Shahmeena Husain, principal secretary, will be to facilitate the technical team. 'We will facilitate the technical team as it will be a task to convince people to give samples.' Apart from name, education, medical history, information collected would include genealogical tree and addictions, physical characteristics like height, weight, BP, blood sugar, and waist measurement. The analysis After the samples have been collected, they will be stored at GBRC, where haematological and biochemical analysis of blood samples will take place. 'First, when the samples come from the field to the lab in Gandhinagar, they will be given Unique IDs. So those who receive the samples will neither know the gender nor the tribe of the person whose sample they are running through the process. This first round of encryption will be stored in our servers. Then, when it goes into the final process of Whole Genome Sequencing (WGS), the data will be encrypted for the second time,' said a researcher close to the project. Joshi said Odisha and Madhya Pradesh, which have 22% and 21% tribal population respectively, have shown interest in the project. 'Modalities on whether they want to be a part of it or contribute to it will be decided by the state, but if they approach us, we are ready.'
Time Business News
17-07-2025
- Health
- Time Business News
Tirzepatide Treatment for in Bradenton and Lakewood Ranch
Losing weight is a journey that often involves much more than just diet and exercise. Many individuals struggle with long-term weight management despite their best efforts. In recent years, medical science has taken significant steps to address this issue with treatments that support sustainable results. One such promising solution is Tirzepatide, a new option for those seeking support in their weight loss efforts. In Bradenton and Lakewood Ranch, individuals now have access to this innovative approach through the Gulf Coast Institute of Rejuvenation, where personalized care and modern treatments work hand in hand. Tirzepatide is a new medication that works on the GLP-1 and GIP receptors in the body. These receptors are part of a hormonal system that helps regulate appetite, insulin response, and digestion. By acting on these natural pathways, Tirzepatide helps reduce hunger, improve the feeling of fullness after meals, and support healthier metabolic responses. Unlike many weight loss treatments of the past, Tirzepatide does not rely on stimulants or appetite suppression through harsh chemical pathways. Instead, it mimics the body's own hormones in a way that supports natural, sustained weight loss. The unique action of Tirzepatide is what makes it stand out. It does more than just help people eat less. It helps the body respond better to food by: Slowing down the rate at which food moves through the stomach Increasing insulin production in response to meals Reducing blood sugar levels Supporting a feeling of fullness longer after eating This combined effect leads to fewer cravings, better control over portions, and gradual, long-term weight reduction. Many patients find that their relationship with food begins to change in a positive way while on treatment. Those who begin Tirzepatide treatment often notice several physical and emotional improvements. While results can vary depending on individual factors, some of the common benefits include: Effective weight reduction over time without extreme dieting over time without extreme dieting Better appetite regulation , which makes sticking to healthier eating habits more achievable , which makes sticking to healthier eating habits more achievable Improved energy levels as the body adjusts to a healthier weight as the body adjusts to a healthier weight Enhanced metabolic function, which can support overall wellness and reduce risks associated with weight-related health concerns Additionally, Tirzepatide is administered only once a week, making it easy to fit into even the busiest lifestyles. This convenience has helped many people stay consistent with their treatment plan. The Gulf Coast Institute of Rejuvenation takes a thoughtful and individualized approach to every patient's care. Before beginning Tirzepatide treatment, patients go through a comprehensive evaluation. This may include a review of medical history, a discussion about lifestyle and nutrition habits, and body measurements that help set realistic goals. Each treatment plan is crafted with the individual's unique needs in mind. The team monitors progress regularly, checking not only weight but also other factors like energy levels, appetite changes, and overall well-being. Adjustments can be made along the way to make sure the plan remains effective and supportive. If you live in or near Bradenton and Lakewood Ranch, access to Tirzepatide treatment means you no longer have to travel far to find a modern, effective solution for weight concerns. The Gulf Coast Institute of Rejuvenation offers the expertise and support needed to make the most of this breakthrough option. Unlike one-size-fits-all diets or temporary fixes, Tirzepatide supports a longer-term approach. It addresses the hormonal and biological reasons behind overeating and weight retention. When combined with education, coaching, and support, the potential for success is even greater. Whether your goal is to lose weight for better health, improved mobility, or simply to feel better in your own skin, Tirzepatide offers a new direction that's both practical and science-based. Starting a new treatment can feel overwhelming, but the team at Gulf Coast Institute of Rejuvenation makes it easier with continuous support. Patients are guided every step of the way. From helping manage side effects to adjusting dosages if needed, their commitment ensures a smooth experience. Support also includes nutrition coaching and lifestyle tips that align with the effects of Tirzepatide, giving patients the best chance to reach their goals. Many find that this well-rounded approach keeps motivation high and builds healthier habits along the way. For many, the journey toward weight wellness has been filled with frustration. Tirzepatide offers a refreshing option grounded in science and personalized care. At Gulf Coast Institute of Rejuvenation, patients in Bradenton and Lakewood Ranch are finding new hope and real progress through this effective treatment. If you've been searching for a way to manage your weight with medical support, Tirzepatide treatment for weight loss in Bradenton and Lakewood Ranch may be worth exploring. The blend of professional guidance, patient-focused care, and innovative medication creates a supportive environment for lasting change. What is the difference between Tirzepatide and other weight loss medications? Tirzepatide works on both GLP-1 and GIP receptors, which helps regulate blood sugar and appetite more effectively than treatments that focus on only one pathway. It mimics the body's own natural hormones rather than using stimulants or chemicals that can cause unwanted side effects. How quickly can results be expected? Results can vary from person to person. Some patients notice changes in appetite and weight within a few weeks, while others may take longer. The key is consistency and working with a provider to track progress. Is Tirzepatide safe for everyone? Not everyone is a candidate for Tirzepatide. Individuals with certain health conditions or who are on specific medications may not be eligible. A full medical evaluation is needed to determine if it is the right fit. Can Tirzepatide help with conditions like prediabetes? Yes, Tirzepatide has been shown to support better blood sugar control and improve insulin sensitivity, which can be beneficial for individuals with prediabetes or metabolic concerns. Do I need to follow a specific diet while on Tirzepatide? While there is no required diet, patients are encouraged to adopt healthier eating habits for the best results. The appetite control that Tirzepatide provides makes it easier to follow a balanced diet without feeling deprived. TIME BUSINESS NEWS
News18
17-07-2025
- Health
- News18
Weight Loss Drugs: What You're Not Hearing About GLP-1 And GIP Based Injectables For Weight Loss
Weight loss drugs: Real success is about taking control, gaining confidence, and achieving the energy to live life to the full, not simply shedding kilos. Discussions on weight loss have been going on for decades, but the discussion has evolved significantly in the last few years. Increasingly, people are turning to weight loss alternatives like injections, moving beyond just diet and exercise regimens. In this trend GLP-1-based injectables—which help manage blood sugar and support weight loss are becoming increasingly popular. While these injections may seem like an easy and almost immediate fix, an important part of the conversation is often left out: the need for careful eligibility assessment, continuous medical oversight, and safety concerns. These discussions leave out the real reasons behind why we gain weight, and the impact of our own lifestyles and habits. Dr. Anju Ghei, MBBS, PGCRT, Head – Preventive Health, VLCC shares all you need to know: These injectable drugs were initially approved for treating type 2 diabetes and are now also approved to manage obesity. They work by mimicking our natural hormones in the gut, GLP-1 and GIP, which help the body release insulin, slow stomach emptying, and signal a feeling of fullness, thus reducing appetite. In addition, GIP also regulates fat metabolism. By doing so, they assist in the weight loss of up to 10–20% of body weight as well as improvement in metabolic parameters. For people dealing with Type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea, PCOS, or other obesity-related health issues, these beneficial effects can be truly life-changing. But these medications are not a magic bullet, and certainly not for everyone. Clinical evidence shows that weight regain is common once the drugs are discontinued, especially when not supported by holistic lifestyle changes. Additionally, they may cause side effects such as nausea, gastrointestinal disturbances, constipation, or bloating. In rare cases, serious complications like pancreatitis, gallbladder issues, or allergic reactions may arise. Moreover, rapid weight loss itself can result in muscle loss, skin laxity, nutrient deficiencies, electrolyte imbalance, and hormonal imbalance, with symptoms like fatigue, anxiety and mood swings. This is why careful eligibility assessment and close medical monitoring are both essential throughout the weight-loss journey. Weight Loss: More Than Numbers Weight loss isn't just about losing kilos, it's about rebalancing many parts of your system. That means balancing hormones, fixing your gut health, sleeping better, controlling stress, staying active and addressing emotional triggers. Injectables may get the ball rolling, but without also identifying and fixing the underlying issues, the results do not last. These drugs must be used under proper medical guidance only, with detailed health profiling and systematic lifestyle guidance. They are most appropriate for people with certain medical conditions for which changing lifestyle alone hasn't helped. So, What's the Alternative? A better approach for long lasting benefits, even after the drugs are discontinued, is integrated wellness. By integrating wellness practices of nutrition (working around whole foods and conscientious calorie management), physical exercise, emotional well-being (stress reduction, behavioural therapy), and habituated lifestyle routines, this approach offers lifelong benefits. Though this pathway takes more time, discipline, and commitment, it provides something injectables can't: side-effect-free, lasting transformation. It's the best approach for those who do not have extreme metabolic disorders, desire self-control over their own health, and are not afraid to construct their own change, brick by brick. The best strategy, therefore, is to balance both, but with expert supervision. Injectables can provide the initial thrust, but they deliver real benefits only when they are part of a tailored plan that addresses physical, emotional, and metabolic well-being. Begin a conversation with your doctor. Monitor not only your weight, but also your energy, sleep, digestion, and mood. Long-term weight loss is about consistency, not perfection. GLP-1 Injectables might be part of the process but should not be the end goal. Real success is about taking control, gaining confidence, and achieving the energy to live life to the full, not simply shedding kilos. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
